Evaluation of prostaglandin E1 therapy for sudden deafness.
Prostaglandin E1, a vasodilator and potent inhibitor of platelet aggregation, was administered by intravenous drip infusion to 51 patients who had sudden deafness. The results were compared with results from 362 patients who received no prostaglandin E1 therapy. There was no significant difference in outcome between patients who received prostaglandin E1 therapy and those who did not receive prostaglandin E1 therapy.
Nakashima
T
T
Department of Otorhinolaryngology, Nagoya University School of Medicine, Japan.
Kuno
K
K
Yanagita
N
N
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D005260:Female; D003639:Hearing Loss, Sudden / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012189:Retrospective Studies
D000527:Alprostadil